In spring 2025, EU-OPENSCREEN confirmed the new membership of Dr. Thomas Lundbäck to its Scientific and Ethical Advisory Board (SEAB). As the SEAB’s new industry-focused appointee, Dr. Lundbäck brings insights from his over 30 years of experience in life science research across academia and industry to advise EU-OPENSCREEN on its scientific contributions and future directions.  

Dr. Thomas Lundbäck is Senior Director at AstraZeneca R&D, where he leads a department within Discovery Sciences focused on profiling small molecules, PROTACs, antisense oligonucleotides, and siRNAs to develop new medicines. His team supports research in cardiovascular, renal, metabolic, respiratory, and inflammatory diseases, and provides early assessment of drug metabolism and pharmacokinetics (DMPK) globally within AstraZeneca. 

In addition to his role at AstraZeneca, Dr. Lundbäck chairs the steering groups for the Chemical Biology Consortium Sweden (CBCS)—a national infrastructure for chemical biology—and the Chemical Biology and Genome Engineering platform at Science for Life Laboratories in Stockholm. 

Dr. Lundbäck earned his PhD in biophysics from Karolinska Institutet and completed postdoctoral research at University College London and Yale University. He began his industry career at Pharmacia & Upjohn (later Biovitrum) before returning to Karolinska Institutet to join CBCS, where he contributed to the development and adoption of the cellular thermal shift assay (CETSA) in drug discovery. 

Dr. Lundbäck is deeply passionate about bridging preclinical and clinical research by combining detailed mechanistic studies with disease-relevant models. He brings a broad external network and is an experienced organizer of scientific meetings, including the ELRIG Therapeutic OLIGOs meeting and the European Chemical Biology Symposium. His previous external engagements include service with SLAS, ELRIG, and the Industry Liaison Office for the Horizon Europe project EU-OPENSCREEN-DRIVE (Grant ID 823893). 

Please join us in welcoming Dr. Lundbäck as a valuable new member of our SEAB. We are honored to bring Dr. Lundbäck’s insights into our organization and look forward to strong collaborations throughout his tenure on the SEAB.